30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Stryker

$2,212MM, +6% (U.S. $1,458MM, +5%; ex-U.S. $754MM, +9%; Trauson +2%)

Reconstructive $979MM, +8% (U.S. +6%, ex-U.S. +9%)

  • Hips $319MM, +6% (U.S. +6%, ex-U.S. +6%)
  • Knees $340MM, +5% (U.S. +2%, ex-U.S. +10%)
  • Trauma/Extremities $266MM, +17% (U.S. +19%, ex-U.S. +15%; Foot/ankle +28% WW, +34% U.S.)

MedSurg Equipment $819MM, +5% (U.S. +4%, ex-U.S. +6%)

  • Endoscopy $274MM, +5% (U.S. +5%, ex-U.S. +4%)

Neurotechnology/Spine $414MM, +8% (U.S. +6%, ex-U.S. +10%)

  • Neurotechnology $227MM, +10% (U.S. +10%, ex-U.S. +10%)
  • Spine $187MM, +5% (U.S. +3%, ex-U.S. +11%)

Overall growth excludes acquisitions. MedSurg includes patient handling and emergency medical equipment.

  • Emerging markets posting double-digit growth
  • Knee sales still feeling impact of ShapeMatch recall; filed OtisMed 510(k) in 2Q
  • Trauma led by new products, strong foot/ankle growth
  • Orthovita starting to have more positive impact in trauma than in previous year